logo
Share SHARE
FONT-SIZE Plus   Neg

Actelion Posts Profit In Q2; Sees Earnings Growth For Full Year - Update

Swiss pharmaceutical firm Actelion Ltd. (ALIOF.PK) reported Thursday a profit for the second quarter, as the company recorded litigation provisions last year. Actelion said it now expects full-year 2012 core earnings to grow in the mid single-digit percentage range, while it had issued a flat core earnings forecast earlier.

Further, on the same 2012 basis, the company expects to maintain core earnings in 2013 at the projected 2012 level, in local currencies, and expects to return to single-digit growth in 2014 and double-digit growth by 2015.

Andrew Oakley, chief financial officer, said the company continues to expect product sales to decrease in low single-digit range for the full year 2012. In addition, Actelion expects to include a restructuring charge for full year, with exact amount yet to be determined.

Jean-Paul Clozel, M.D. and chief executive officer said, "I am very pleased, that our efforts to control costs are already having an impact on profitability....I strongly believe that through the execution of our strategy, with our available assets as well as the cost control measures we have committed to, Actelion is well-positioned for sustainable core earnings growth and greater shareholder returns in the future."

In the second quarter, the company posted a net income of 128.68 million Swiss francs or 1.09 francs per share, compared to a net loss of 408.56 million francs or 3.43 francs per share reported last year. In the prior-year quarter, the company recorded litigation provisions totaling 485.21 million francs.

Total operating expenses dropped to 285.46 million francs from 829.43 million francs in the previous year.

Total net revenues grew to 447.55 million francs from 441.69 million francs in the prior-year quarter. Revenues from Product sales increased to 445.94 million francs from 440.05 francs in the preceding year. Contract revenues were 1.61 million francs, compared to 1.64 million francs a year earlier.

On Frankfurt's Xetra, the shares closed Wednesday's regular trading at 34.10 euros, up 0.33 percent.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Toll Brothers, Inc. (TOL), the nation's leading builder of luxury homes, reported second-quarter net income of $89.1 million, or $0.51 per share, compared to $67.9 million, or $0.37 per share, prior year. Pre-tax income increased to $140.4 million from $86.5 million. On average, 18 analysts polled by... German conglomerate Bayer AG said it has made an all-cash offer to acquire U.S. competitor Monsanto for $122 per share or an aggregate value of $62 billion. Bayer expects the deal to reinforce it as a Life Science company with a deepened position. Responding to recent media reports, agricultural products giant Monsanto recently had disclosed that it had received an unsolicited proposal from Bayer. Agricultural machinery maker Deere & Co. reported Friday lower profit in its second quarter, reflecting weak equipment sales. Profit and net sales, however, topped analysts' estimates. Further, the company cut its forecast for fiscal 2016 profit, while updated sales view.
comments powered by Disqus
Follow RTT